Evidence map›Paper›PMID 26353844›Full record

ReviewNeurotoxicity research2016

Cannabinoid Ligands and Alcohol Addiction: A Promising Therapeutic Tool or a Humbug?

Patrycja Kleczkowska, Irena Smaga, Małgorzata Filip, Magdalena Bujalska-Zadrozny

Open access · hybridAbstract readReview
In one paragraph

Review in Neurotoxicity research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Highway to hell or magic smoke? The dose-dependence of ΔLearning & memory (Cold Spring Harbor, N.Y.) · 2018
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Patrycja KleczkowskaDepartment of Pharmacodynamics, Centre for Preclinical Research and Technology (CEPT), Medical University of Warsaw, Banacha 1B, 02-097, Warsaw, Poland.
Irena SmagaDepartment of Toxicology, Faculty of Pharmacy, Jagiellonian University, College of Medicum, Medyczna 9, 30-688, Kraków, Poland.
Małgorzata FilipDepartment of Toxicology, Faculty of Pharmacy, Jagiellonian University, College of Medicum, Medyczna 9, 30-688, Kraków, Poland.
Magdalena Bujalska-ZadroznyDepartment of Pharmacodynamics, Centre for Preclinical Research and Technology (CEPT), Medical University of Warsaw, Banacha 1B, 02-097, Warsaw, Poland. magdalena.bujalska@wum.edu.pl.
Medical University of Warsaw · PLJagiellonian University · PLMaj Institute of Pharmacology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The vast therapeutic potential of cannabinoids of both synthetic and plant-derived origins currently makes these compounds the focus of a growing interest. Although cannabinoids are still illicit drugs, their possible clinical usefulness, including treatment of acute or neuropathic pain, have been suggested by several studies. In addition, some observations indicate that cannabinoid receptor antagonists may be useful for the treatment of alcohol dependence and addiction, which is a major health concern worldwide. While the synergism between alcohol and cannabinoid agonists (in various forms) creates undesirable side effects when the two are consumed together, the administration of CB1 antagonists leads to a significant reduction in alcohol consumption. Furthermore, cannabinoid antagonists also mitigate alcohol withdrawal symptoms. Herein, we present an overview of studies focusing on the effects of cannabinoid ligands (agonists and antagonists) during acute or chronic consumption of ethanol.

Indexed as

LigandsAlcoholismAnimalsCannabinoidsClinical Trials as TopicDrug Evaluation, PreclinicalHumansReceptor, Cannabinoid, CB1CannabinoidsLigandsReceptor, Cannabinoid, CB1AlcoholCannabinoidsCo-administrationEndocannabinoid system

Identifiers

PMID26353844
PMCPMC4701763
OpenAlexW2127910204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.